HALO - HALOZYME THERAPEUTICS, INC.
IEX Last Trade
48.03
0.120 0.250%
Share volume: 12,606
Last Updated: Thu 26 Dec 2024 08:29:47 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$47.91
0.12
0.25%
Fundamental analysis
79%
Profitability
100%
Dept financing
28%
Liquidity
75%
Performance
71%
Performance
5 Days
0.81%
1 Month
-0.52%
3 Months
-16.52%
6 Months
-8.58%
1 Year
27.21%
2 Year
-17.31%
Key data
Stock price
$48.03
DAY RANGE
$47.26 - $47.97
52 WEEK RANGE
$34.05 - $65.53
52 WEEK CHANGE
$27.97
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Helen I. Torley
Region: US
Website: halozyme.com
Employees: 390
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: halozyme.com
Employees: 390
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company. Its products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL)
Recent news